Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis.

CONCLUSIONS: Pioglitazone should be considered in patients with or at high risk of T2DM for the prevention of cardiovascular endpoints, especially in those with a history of established CVD who might benefit the most. Robust reductions in progression of renal disease are seen regardless of baseline renal function degree.
PMID: 31822895 [PubMed - as supplied by publisher]

Source: The Journal of Clinical Endocrinology and Metabolism - December 10, 2019 Category: Endocrinology Authors: Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y Tags: J Clin Endocrinol Metab Source Type: research